Marie Thibault
Stock Analyst at BTIG
(4.12)
# 473
Out of 4,944 analysts
76
Total ratings
59.15%
Success rate
10.93%
Average return
Main Sectors:
Stocks Rated by Marie Thibault
| Stock | Action | Price Target | Current | Upside | Ratings | Updated | |
|---|---|---|---|---|---|---|---|
| ABT Abbott Laboratories | Maintains: Buy | $148 → $145 | $131.02 | +10.67% | 12 | Jul 18, 2025 | |
| ATRC AtriCure | Maintains: Buy | $58 → $52 | $35.82 | +45.17% | 7 | Apr 30, 2025 | |
| BSX Boston Scientific | Maintains: Buy | $120 → $124 | $102.64 | +20.81% | 10 | Apr 23, 2025 | |
| OBIO Orchestra BioMed Holdings | Initiates: Buy | $12 | $2.72 | +341.18% | 1 | Mar 20, 2025 | |
| EMBC Embecta | Upgrades: Buy | $26 | $13.32 | +95.20% | 2 | Nov 27, 2024 | |
| PODD Insulet | Maintains: Buy | $260 → $270 | $309.63 | -12.80% | 4 | Nov 8, 2024 | |
| MASI Masimo | Maintains: Buy | $166 → $170 | $150.13 | +13.24% | 3 | Oct 14, 2024 | |
| ESTA Establishment Labs Holdings | Maintains: Buy | $62 → $65 | $33.62 | +93.34% | 8 | Oct 14, 2024 | |
| HAE Haemonetics | Initiates: Buy | $112 | $52.23 | +114.44% | 1 | Sep 10, 2024 | |
| DXCM DexCom | Maintains: Buy | $156 → $120 | $80.17 | +49.68% | 7 | Jul 26, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Downgrades: Neutral | n/a | $3.16 | - | 2 | Jun 25, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Downgrades: Neutral | n/a | $2.45 | - | 3 | Oct 6, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Buy | $19 → $20 | $10.88 | +83.82% | 3 | Aug 16, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Buy | $165 → $140 | $162.28 | -13.73% | 7 | Jun 8, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Buy | $9 → $7 | $1.48 | +372.97% | 1 | Jun 24, 2022 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Downgrades: Neutral | n/a | $3.86 | - | 3 | Oct 13, 2021 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Downgrades: Neutral | n/a | $0.47 | - | 1 | Jan 21, 2021 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Buy | $11 → $6 | $216.66 | -97.23% | 1 | Apr 9, 2020 |
Abbott Laboratories
Jul 18, 2025
Maintains: Buy
Price Target: $148 → $145
Current: $131.02
Upside: +10.67%
AtriCure
Apr 30, 2025
Maintains: Buy
Price Target: $58 → $52
Current: $35.82
Upside: +45.17%
Boston Scientific
Apr 23, 2025
Maintains: Buy
Price Target: $120 → $124
Current: $102.64
Upside: +20.81%
Orchestra BioMed Holdings
Mar 20, 2025
Initiates: Buy
Price Target: $12
Current: $2.72
Upside: +341.18%
Embecta
Nov 27, 2024
Upgrades: Buy
Price Target: $26
Current: $13.32
Upside: +95.20%
Insulet
Nov 8, 2024
Maintains: Buy
Price Target: $260 → $270
Current: $309.63
Upside: -12.80%
Masimo
Oct 14, 2024
Maintains: Buy
Price Target: $166 → $170
Current: $150.13
Upside: +13.24%
Establishment Labs Holdings
Oct 14, 2024
Maintains: Buy
Price Target: $62 → $65
Current: $33.62
Upside: +93.34%
Haemonetics
Sep 10, 2024
Initiates: Buy
Price Target: $112
Current: $52.23
Upside: +114.44%
DexCom
Jul 26, 2024
Maintains: Buy
Price Target: $156 → $120
Current: $80.17
Upside: +49.68%
Jun 25, 2024
Downgrades: Neutral
Price Target: n/a
Current: $3.16
Upside: -
Oct 6, 2023
Downgrades: Neutral
Price Target: n/a
Current: $2.45
Upside: -
Aug 16, 2023
Maintains: Buy
Price Target: $19 → $20
Current: $10.88
Upside: +83.82%
Jun 8, 2023
Maintains: Buy
Price Target: $165 → $140
Current: $162.28
Upside: -13.73%
Jun 24, 2022
Maintains: Buy
Price Target: $9 → $7
Current: $1.48
Upside: +372.97%
Oct 13, 2021
Downgrades: Neutral
Price Target: n/a
Current: $3.86
Upside: -
Jan 21, 2021
Downgrades: Neutral
Price Target: n/a
Current: $0.47
Upside: -
Apr 9, 2020
Maintains: Buy
Price Target: $11 → $6
Current: $216.66
Upside: -97.23%